Lilly's Jardiance slows kidney disease progression in diabetics
(Reuters) - Eli Lilly and Co's Jardiance diabetes drug slashed the risk of progressive kidney disease in adults with type 2 diabetes in a large trial that had already proved the medication's ability to greatly reduce cardiovascular deaths and hospitalizations for heart failure.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Health | Heart | Heart Failure | Jardiance | Urology & Nephrology